세계의 단일클론항체 치료제 시장 보고서(2025년)

Monoclonal antibody therapeutics are lab-engineered molecules designed to function as substitute antibodies that can specifically recognize and bind to antigens found on cancer cells, pathogens, or components of the immune system. These therapies are developed to neutralize disease-causing agents or deliver targeted treatments directly to affected cells, making them highly effective in addressing a wide range of conditions, including cancer, autoimmune disorders, and infectious diseases.

The primary product types in monoclonal antibody therapeutics include naked antibodies, fusion proteins, antibody fragments, conjugates, and multi-specific antibodies. Naked monoclonal antibodies are lab-produced proteins that operate independently, without being linked to drugs or radioactive substances. These products are applied across various therapeutic areas, such as autoimmune and inflammatory disorders, oncology, hematology, ophthalmology, and more, for the treatment of conditions like cancer, autoimmune diseases, infections, and hematological disorders. The end users encompass a diverse group, including hospitals, private clinics, and research institutions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The monoclonal antibody therapeutics market research report is one of a series of new reports from The Business Research Company that provides monoclonal antibody therapeutics market statistics, including monoclonal antibody therapeutics industry global market size, regional shares, competitors with a monoclonal antibody therapeutics market share, detailed monoclonal antibody therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the monoclonal antibody therapeutics industry. This monoclonal antibody therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The monoclonal antibody therapeutics market size has grown rapidly in recent years. It will grow from $199.98 billion in 2024 to $224.62 billion in 2025 at a compound annual growth rate (CAGR) of 12.3%. The growth during the historical period can be attributed to the increasing prevalence of chronic diseases, rising demand for targeted therapies, expanded use in oncology treatments, growth in biopharmaceutical manufacturing, government support for biologics research, and the rising incidence of autoimmune disorders.

The monoclonal antibody therapeutics market size is expected to see rapid growth in the next few years. It will grow to $354.11 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth anticipated in the forecast period can be attributed to the expansion of personalized medicine, a growing geriatric population, broader indications for approved monoclonal antibodies, rising healthcare expenditures, and increased awareness among healthcare professionals. Key trends expected during this period include the development of bispecific antibodies, advancements in hybridoma technology, the application of AI in antibody discovery, progress in glycoengineering, the adoption of continuous bioprocessing methods, and the use of gene editing tools to enhance antibody expression.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the monoclonal antibody therapeutics market. Autoimmune diseases occur when the immune system mistakenly attacks the body's own healthy tissues, treating them as foreign threats. This results in chronic inflammation and tissue damage. Environmental changes, including greater exposure to pollutants and shifts in microbial environments, are believed to contribute to the growing number of autoimmune conditions by triggering abnormal immune responses in genetically susceptible individuals. Monoclonal antibody therapeutics offer targeted treatment by blocking specific immune pathways that cause inflammation and damage, which helps alleviate symptoms and slow disease progression. For example, in March 2023, a report from the Office for Health Improvement & Disparities, a UK government department, indicated that in 2022, 17.6% of individuals aged 16 and older reported having a long-term musculoskeletal condition, often associated with autoimmune disease, compared to 17.0% in 2021. This trend highlights the increasing demand for effective therapies and supports the growth of the monoclonal antibody therapeutics market.

Companies in the monoclonal antibody therapeutics sector are developing bispecific monoclonal antibodies to improve treatment outcomes by targeting two antigens or epitopes simultaneously. These specialized antibodies are engineered to bind to either two separate antigens or two distinct sites on the same antigen. In March 2024, Roche Holding AG, a pharmaceutical company based in Switzerland, launched Vabysmo (faricimab-svoa), a bispecific monoclonal antibody developed to treat eye diseases such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema due to retinal vein occlusion (RVO). The drug targets both VEGF-A and Angiopoietin-2 (Ang-2), improving vascular stability and reducing fluid buildup in the retina. Its dual-action mechanism enables longer intervals between doses-up to four months, helping reduce the treatment burden for patients.

In February 2024, AbbVie Inc., a biopharmaceutical company based in the United States, formed a partnership with OSE Immunotherapeutics SA to develop a new monoclonal antibody therapy focused on chronic and severe inflammation. The collaboration centers on the development and commercialization of OSE-230, a monoclonal antibody designed to activate the ChemR23 receptor, which plays a role in resolving inflammation. The goal is to provide improved therapeutic outcomes for patients dealing with serious inflammatory diseases. OSE Immunotherapeutics SA is a biotechnology company based in France that specializes in creating innovative immunotherapies, including monoclonal antibodies, for cancer and autoimmune disorders.

Major players in the monoclonal antibody therapeutics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Daiichi Sankyo Company Limited, UCB S.A., Genmab A/S, ADC Therapeutics, Arcus Biosciences, and Y-mAbs Therapeutics.

North America was the largest region in the monoclonal antibody therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in monoclonal antibody therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the monoclonal antibody therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The monoclonal antibody therapeutics market consists of sales of murine monoclonal antibodies, humanized monoclonal antibodies, antibody-drug conjugates, anti-infective monoclonal antibodies, and immune effector cell engagers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Monoclonal Antibody Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on monoclonal antibody therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for monoclonal antibody therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The monoclonal antibody therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Naked; Fusion Protein; Antibody Fragment; Conjugate; Multi-Specific
• 2) By Therapy Area: Autoimmune And Inflammatory Disorders; Oncology; Hematology; Ophthalmology; Other Therapy Areas
• 3) By Application: Cancer; Autoimmune Diseases; Infection; Hematological Diseases; Other Applications
• 4) By End User: Hospitals; Private Clinics; Research Institute
• Subsegments:
• 1) By Naked: Fully Human Antibodies; Humanized Antibodies; Chimeric Antibodies
• 2) By Fusion Protein: Receptor Fusion Proteins; Ligand Fusion Proteins
• 3) By Antibody Fragment: Single-Chain Variable Fragment; Fab Fragments; Diabodies
• 4) By Conjugate: Antibody-Drug Conjugates; Radioimmunoconjugates; Immunotoxins
• 5) By Multi-Specific: Bispecific Antibodies; Trispecific Antibodies; T-Cell Engagers
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Bayer Aktiengesellschaft; Sanofi SA; Bristol-Myers Squibb Company; AstraZeneca plc; Novartis AG; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Boehringer Ingelheim International GmbH; Amgen Inc.; Regeneron Pharmaceuticals Inc.; Biogen Inc.; Daiichi Sankyo Company Limited; UCB S.A.; Genmab A/S; ADC Therapeutics; Arcus Biosciences; Y-mAbs Therapeutics
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Monoclonal Antibody Therapeutics Market Characteristics

3. Monoclonal Antibody Therapeutics Market Trends And Strategies

4. Monoclonal Antibody Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Monoclonal Antibody Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Monoclonal Antibody Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Monoclonal Antibody Therapeutics Market Growth Rate Analysis
• 5.4. Global Monoclonal Antibody Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Monoclonal Antibody Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Monoclonal Antibody Therapeutics Total Addressable Market (TAM)

6. Monoclonal Antibody Therapeutics Market Segmentation

• 6.1. Global Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Naked
• Fusion Protein
• Antibody Fragment
• Conjugate
• Multi-Specific
• 6.2. Global Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autoimmune And Inflammatory Disorders
• Oncology
• Hematology
• Ophthalmology
• Other Therapy Areas
• 6.3. Global Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer
• Autoimmune Diseases
• Infection
• Hematological Diseases
• Other Applications
• 6.4. Global Monoclonal Antibody Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Private Clinics
• Research Institute
• 6.5. Global Monoclonal Antibody Therapeutics Market, Sub-Segmentation Of Naked, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fully Human Antibodies
• Humanized Antibodies
• Chimeric Antibodies
• 6.6. Global Monoclonal Antibody Therapeutics Market, Sub-Segmentation Of Fusion Protein, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Receptor Fusion Proteins
• Ligand Fusion Proteins
• 6.7. Global Monoclonal Antibody Therapeutics Market, Sub-Segmentation Of Antibody Fragment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Chain Variable Fragment
• Fab Fragments
• Diabodies
• 6.8. Global Monoclonal Antibody Therapeutics Market, Sub-Segmentation Of Conjugate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibody-Drug Conjugates
• Radioimmunoconjugates
• Immunotoxins
• 6.9. Global Monoclonal Antibody Therapeutics Market, Sub-Segmentation Of Multi-Specific, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bispecific Antibodies
• Trispecific Antibodies
• T-Cell Engagers

7. Monoclonal Antibody Therapeutics Market Regional And Country Analysis

• 7.1. Global Monoclonal Antibody Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Monoclonal Antibody Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Monoclonal Antibody Therapeutics Market

• 8.1. Asia-Pacific Monoclonal Antibody Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Monoclonal Antibody Therapeutics Market

• 9.1. China Monoclonal Antibody Therapeutics Market Overview
• 9.2. China Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Monoclonal Antibody Therapeutics Market

• 10.1. India Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Monoclonal Antibody Therapeutics Market

• 11.1. Japan Monoclonal Antibody Therapeutics Market Overview
• 11.2. Japan Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Monoclonal Antibody Therapeutics Market

• 12.1. Australia Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Monoclonal Antibody Therapeutics Market

• 13.1. Indonesia Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Monoclonal Antibody Therapeutics Market

• 14.1. South Korea Monoclonal Antibody Therapeutics Market Overview
• 14.2. South Korea Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Monoclonal Antibody Therapeutics Market

• 15.1. Western Europe Monoclonal Antibody Therapeutics Market Overview
• 15.2. Western Europe Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Monoclonal Antibody Therapeutics Market

• 16.1. UK Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Monoclonal Antibody Therapeutics Market

• 17.1. Germany Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Monoclonal Antibody Therapeutics Market

• 18.1. France Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Monoclonal Antibody Therapeutics Market

• 19.1. Italy Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Monoclonal Antibody Therapeutics Market

• 20.1. Spain Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Monoclonal Antibody Therapeutics Market

• 21.1. Eastern Europe Monoclonal Antibody Therapeutics Market Overview
• 21.2. Eastern Europe Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Monoclonal Antibody Therapeutics Market

• 22.1. Russia Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Monoclonal Antibody Therapeutics Market

• 23.1. North America Monoclonal Antibody Therapeutics Market Overview
• 23.2. North America Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Monoclonal Antibody Therapeutics Market

• 24.1. USA Monoclonal Antibody Therapeutics Market Overview
• 24.2. USA Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Monoclonal Antibody Therapeutics Market

• 25.1. Canada Monoclonal Antibody Therapeutics Market Overview
• 25.2. Canada Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Monoclonal Antibody Therapeutics Market

• 26.1. South America Monoclonal Antibody Therapeutics Market Overview
• 26.2. South America Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Monoclonal Antibody Therapeutics Market

• 27.1. Brazil Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Monoclonal Antibody Therapeutics Market

• 28.1. Middle East Monoclonal Antibody Therapeutics Market Overview
• 28.2. Middle East Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Monoclonal Antibody Therapeutics Market

• 29.1. Africa Monoclonal Antibody Therapeutics Market Overview
• 29.2. Africa Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Monoclonal Antibody Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Monoclonal Antibody Therapeutics Market Competitive Landscape
• 30.2. Monoclonal Antibody Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Monoclonal Antibody Therapeutics Market Other Major And Innovative Companies

• 31.1. Bayer Aktiengesellschaft
• 31.2. Sanofi SA
• 31.3. Bristol-Myers Squibb Company
• 31.4. AstraZeneca plc
• 31.5. Novartis AG
• 31.6. GlaxoSmithKline plc
• 31.7. Takeda Pharmaceutical Company Limited
• 31.8. Eli Lilly and Company
• 31.9. Boehringer Ingelheim International GmbH
• 31.10. Amgen Inc.
• 31.11. Regeneron Pharmaceuticals Inc.
• 31.12. Biogen Inc.
• 31.13. Daiichi Sankyo Company Limited
• 31.14. UCB S.A.
• 31.15. Genmab A/S

32. Global Monoclonal Antibody Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Monoclonal Antibody Therapeutics Market

34. Recent Developments In The Monoclonal Antibody Therapeutics Market

35. Monoclonal Antibody Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Monoclonal Antibody Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Monoclonal Antibody Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Monoclonal Antibody Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer